Hershey AD et al.
Headache. 2007;47:73-80. In 1550 paediatric patients (mean age 13.3 years) attending a tertiary care centre with frequent headaches, the mean total coenzyme Q10 (CoQ10) level was 0.60 microg/mL; 32.9% of patients had CoQ10 levels below the reference range. Patients with low CoQ10 were recommended to start 1 to 3 mg/kg per day of CoQ10 in liquid gel capsule formulation. At follow-up, the total CoQ10 level had improved to 1.20 microg/mL, headache frequency had improved from 19.2 to 12.5 and headache disability assessed with PedMIDAS had improved from 47.4 to 22.8.
Open label trial of coenzyme Q10 as a migraine preventive.
Rozen TD et al.
Cephalalgia. 2002;22:137-41. Of 32 adult patients with a history of episodic migraine with or without aura who received coenzyme Q10 at a dose of 150 mg/day, 61.3% had a >50% reduction in number of days with migraine headache. After 3 months' treatment, there were significant reductions in the average number of days with migraine and frequency of migraine attacks. No side effects were observed with coenzyme Q10.
Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial.
Sándor PS et al.
Neurology. 2005;64:713-5. Coenzyme Q10 (3 x 100 mg/day) was superior to placebo in migraine patients for attack frequency, headache days and days with nausea in the third treatment month and was well tolerated.
No comments:
Post a Comment